Kamada (KMDA) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS
Kamada (NASDAQ:KMDA) announced its quarterly earnings results on Wednesday. The biotechnology company reported $0.16 EPS for the quarter, beating the consensus estimate of $0.06 by $0.10, Morningstar.com reports. The firm had revenue of $35.71 million for the quarter, compared to analyst estimates of $32.90 million. Kamada had a negative return on equity of 1.64% and a negative net margin of 1.27%.
Shares of Kamada (NASDAQ:KMDA) traded down $0.10 during trading hours on Thursday, reaching $5.05. The company’s stock had a trading volume of 10,936 shares, compared to its average volume of 31,034. Kamada has a one year low of $3.75 and a one year high of $8.61. The firm has a market capitalization of $191.56, a P/E ratio of -128.72 and a beta of 1.14. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.71 and a quick ratio of 2.73.
Large investors have recently made changes to their positions in the business. Jane Street Group LLC acquired a new position in shares of Kamada in the 3rd quarter valued at $112,000. Worth Venture Partners LLC acquired a new position in Kamada during the 3rd quarter worth about $246,000. Navellier & Associates Inc acquired a new position in Kamada during the 2nd quarter worth about $303,000. Analyst IMS Investment Management Services Ltd. lifted its stake in Kamada by 125.5% during the 3rd quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock worth $431,000 after acquiring an additional 50,000 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Kamada by 6.5% during the 2nd quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after acquiring an additional 28,382 shares in the last quarter. 6.26% of the stock is owned by institutional investors.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.